▲ Peaking
Health
Exclusive | She was ready to die. Now she’s in remission
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Merck
28 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
Merck licenses a KRAS G12D inhibitor for $400M upfront
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.
◼ Archived
Business
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.
◼ Archived
Business
Merck sees pivotal victory for $3B eye disease prospect
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Cancer Vaccines Market Anticipates Impressive Growth Trajectory at a CAGR of 36% During the Forecast Period (2026-2036)
Recent coverage examines the growing cancer vaccines market alongside Phase 3 mRNA vaccine results and personalised medicine strategies.
◼ Archived
Business
🔮 fades ✓
Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?
Moderna and Merck trial data sparks debate over whether a personalized medicine revolution is beginning.
◼ Archived
Business
🔮 holds ✗
Personalized mRNA cancer vaccines offer new hope. We explain
Personalized mRNA cancer vaccines are gaining momentum following Phase III success in melanoma and expanded global clinical trials.
◼ Archived
Business
🔮 fades ✓
Summit Packs A Punch For Merck's Keytruda
Summit Therapeutics and Akeso report that their cancer drug ivonescimab has met overall survival goals in a Phase 3 lung cancer trial.
◼ Archived
Business
🔮 fades ✗
What it was like to go through a trial that could revolutionize cancer treatment
Moderna and Merck have reported a significant triumph regarding a collaborative cancer vaccine trial that could revolutionize oncology treatment.
◼ Archived
Business
🔮 fades ✓
Moderna, Merck breakthrough could usher in wave of cancer vaccines
11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✗
Congo to receive 70,000 doses of Ervebo Ebola vaccine which has been effective in past outbreaks
The Democratic Republic of the Congo is receiving 70,000 doses of the Ervebo vaccine to combat an unprecedented Ebola outbreak caused by the Bundibugyo strain.
◼ Archived
Business
🔮 fades ✓
Moderna and Merck’s mRNA Melanoma Vaccine Looks Like a Game Changer
Moderna and Merck's mRNA melanoma vaccine is drawing significant attention as a potential game changer according to recent coverage.
◼ Archived
Business
🔮 fades ✗
Moderna Shares Double on Success of mRNA Cancer Vaccine
Moderna shares double following clinical trial results for a personalized mRNA melanoma vaccine developed with Merck.
◼ Archived
Business
🔮 fades ✓
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
Merck and Moderna’s melanoma vaccine hits key survival milestones, sending Moderna's stock soaring.
◼ Archived
Business
🔮 fades ✓
Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial
Moderna stock surges after a partnered melanoma vaccine developed with Merck successfully reduced cancer recurrence in a large-scale clinical trial.
◼ Archived
Business
🔮 fades ✗
Moderna shares soar 60% on melanoma vaccine trial success
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 holds ✓
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
Moderna and Merck report success in a late-stage melanoma trial for their personalized mRNA cancer vaccine.
◼ Archived
Health
🔮 fades ✓
Drugmakers uninterested in Trump’s order to split up MMR vaccine
Pharmaceutical companies are resisting a directive from President Trump to decouple the combined MMR vaccine into separate shots.
◼ Archived
Health
🔮 fades ✗
As FDA makes Lipfendra poster child of CNPV pilot, Merck charts long-term path for first PCSK9 pill
The FDA approves the first oral PCSK9 pill, Lipfendra, as Merck charts a long-term path.
◼ Archived
Health
🔮 fades ✓
Lipfendra vs statins: How these cholesterol-lowering drugs compare
Recent coverage examines how Lipfendra compares to traditional statins for lowering cholesterol.
◼ Archived
Business
🔮 fades ✗
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
Merck & Co. reports mixed Q2 2026 results, lifting sales forecasts on drug strength while cutting profit outlook due to acquisition costs.
◼ Archived
Health
🔮 fades
First person gets new experimental vaccine for Ebola
The world's first human clinical trial for a Bundibugyo ebolavirus vaccine has commenced following the first volunteer's vaccination.
◼ Archived
Business
🔮 fades
With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access
Merck is establishing global access and licensing frameworks for the world's first monthly oral HIV prevention pill ahead of its official approval.
◼ Archived
Business
🔮 fades
Merck gets US FDA nod for first-in-its-class oral cholesterol drug
Merck has achieved a regulatory milestone with the FDA approval of Lipfendra, the first-of-its-kind oral treatment for reducing cholesterol.
◼ Archived
Business
🔮 fades
Game-changing cholesterol pill wins FDA approval after cutting LDL nearly 60%
The FDA has approved Merck's Lipfendra, the first oral PCSK9 drug capable of lowering LDL cholesterol by nearly 60%.
◼ Archived
Business
🔮 holds
The F.D.A. Approves a New Pill to Slash Cholesterol Levels
The FDA has approved a first-of-its-kind daily oral pill from Merck designed to slash cholesterol levels.
◼ Archived
Business
🔮 fades
EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials
A US House committee has launched an investigation into major pharmaceutical companies regarding the use of clinical trial sites in China.
◼ Archived
Business
🔮 holds
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
Merck KGaA, Darmstadt, Germany, has entered into an agreement to acquire Bio-Techne in an all-cash deal valued at $11.3 billion.